Correlation Network Analysis Reveals Relationships between MicroRNAs, Transcription Factor T-bet, and Deregulated Cytokine/Chemokine-Receptor Network in Pulmonary Sarcoidosis
Table 1
Clinical and laboratory data of enrolled patients with pulmonary sarcoidosis.
Characteristics
Sarcoidosis
Regression
Progression
Controls
( = 48)
( = 28)
( = 20)
( = 14)
Age, yrs
47.9 (29–72)
45.8 (29–70)
50.9 (32–72)
39.6 (19–63)
Sex (male/female)
23/25
12/16
11/9
9/5
Smoking (y/n/ex)
0/37/11
0/20/8
0/17/3
0/9/5
Pulmonary/pulmonary plus extrapulmonary involvement
35/13
18/10
17/3
—
CXR stages (I/II)
15/33
10/18
5/15
—
Löfgren’s syndrome (y/n)
7/41
4/24
3/17
—
BALF differential count
% macrophages
75.6 ± 5.8 (40.0–94.0)
74.3 ± 6.6 (40.0–94.0)
77.5 ± 4.5 (60.5–87.4)
92.2 ± 13.5 (83.8–97.4)
% lymphocytes
21.6 ± 5.5 (4.6–49.0)
22.8 ± 6.2 (6.0–49.0)
19.9 ± 4.6 (4.6–36.0)
6.2 ± 2.3 (1.6–11.0)
% neutrophils
2.1 ± 1.6 (0.0–18.0)
2.3 ± 1.8 (0.0–18.0)
1.8 ± 1.2 (0.0–10.0)
1.5 ± 0.8 (0.3–6.0)
% eosinophils
1.3 ± 1.9 (0.0–17.3)
1.3 ± 1.6 (0.0–17.0)
1.4 ± 1.9 (0.0–17.3)
0.3 ± 0.1 (0.3–0.6)
% CD3+#
83.6 ± 6.4 (48.0–98.0)
83.8 ± 7.1 (48.0–96.0)
83.3 ± 5.7 (54.0–98.0)
74.1 ± 7.2 (40.0–92.0)
% CD4+#
64.9 ± 8.8 (23.0–92.0)
66.9 ± 8.9 (27.0–92.0)
62.0 ± 8.9 (23.0–86.0)
45.7 ± 7.3 (22.0–67.0)
% CD8+#
16.8 ± 5.7 (2.0–50.0)
14.4 ± 4.9 (2.0–42.0)
20.3 ± 6.4 (4.0–50.0)
27.4 ± 5.5 (14.0–51.0)
% CD19+#
1.03 ± 1.2 (0.0–14.0)
0.9 ± 1.3 (0.0–14.0)
1.2 ± 1.1 (0.0–8.0)
1.2 ± 0.6 (0.0–3.0)
BALF CD4+/CD8+ ratio
6.8 ± 3.6 (0.8–46.0)
7.9 ± 4.2 (1.1–46.0)
5.3 ± 2.6 (0.8–21.3)
2.0 ± 0.5 (0.5–3.7)
BALF: bronchoalveolar lavage fluid; : number of patients; n: no; y: yes; ex: ex-smoker; CXR: chest X-ray; —: not relevant. Data are presented as mean ± SD (minimum and maximum in parentheses). Data were not available for four patients. % of CD3, CD4, CD8, and CD19 refers to total lymphocyte counts.
